BMP-2 and titanium particles synergistically activate osteoclast formation

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 6, 2014, Pages 461-469

  Sun, S X ^a   Guo, H H ^b   Zhang, J ^c   Yu, B ^b   Sun, K N ^a   Jin, Q H ^a  

^a AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bone morphogenetic protein; Osteoclasts; RANKL; SMAD; Titanium

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CATHEPSIN K; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TITANIUM; TUMOR NECROSIS FACTOR ALPHA; ACID PHOSPHATASE; BMP2 PROTEIN, MOUSE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOREACTIVITY; MACROPHAGE CULTURE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; ISOLATION AND PURIFICATION; MACROPHAGE; METABOLISM; OSTEOLYSIS; TUMOR CELL LINE;

ACID PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; ISOENZYMES; MACROPHAGES; MICE; OSTEOCLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; SMAD PROTEINS; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901664474     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20132966     Document Type: Article

References (40)

1. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. Clin Orthop Relat Res 2001; 393: 71-77, doi: 10.1097/00003086-200112000-00008.
2. Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005; 26: 1271-1286, doi: 10.1016/j.biomaterials.2004.04.035.
3. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001; 83: 902-911, doi: 10.1302/0301-620X. 83B6.10905.
4. Kobayashi A, Freeman MA, Bonfield W, Kadoya Y, Yamac T, Al-Saffar N, et al. Number of polyethylene particles and osteolysis in total joint replacements. A quantitative study using a tissue-digestion method. J Bone Joint Surg Br 1997; 79: 844-848, doi: 10.1302/0301-620X.79B5.7602.
5. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999; 154: 203-210, doi: 10.1016/S0002-9440(10)65266-2.
6. Maloney WJ, James RE, Smith RL. Human macrophage response to retrieved titanium alloy particles in vitro. Clin Orthop Relat Res 1996; 322: 268-278.
7. Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995; 15: 3479-3486.
8. Jensen ED, Pham L, Billington CJ Jr, Espe K, Carlson AE, Westendorf JJ, et al. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010; 109: 672-682.
9. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176, doi: 10.1016/S0092-8674(00)81569-X.
10. Matsuo K. Cross-talk among bone cells. Curr Opin Nephrol Hypertens 2009; 18: 292-297, doi: 10.1097/MNH.0b013e3 2832b75f1.
11. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 2001; 142: 3656-3662.
12. Falany ML, Thames AM III, McDonald JM, Blair HC, McKenna MA, Moore RE, et al. Osteoclasts secrete the chemotactic cytokine mim-1. Biochem Biophys Res Commun 2001; 281: 180-185, doi: 10.1006/bbrc.2001.4307.
13. Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine 2009; 34: 539-550, doi: 10.1097/BRS.0b013e318 1952695.
14. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003; 38: 605-614, doi: 10.1016/S0531-5565(03)00069-X.
15. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci 2006; 1068: 100-109, doi: 10.1196/annals. 1346.013.
16. Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab 2005; 23 (Suppl): 11-15, doi: 10.1007/ BF03026317.
17. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001, doi: 10.1084/jem.188.5.997.
18. Abbas S, Clohisy JC, Abu-Amer Y. Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 2003; 21: 1041-1048, doi: 10.1016/ S0736-0266(03)00081-0.
19. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 1994; 266: 443-448, doi: 10.1126/science.7939 685.
20. Miyanishi K, Trindade MC, Ma T, Goodman SB, Schurman DJ, Smith RL. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/ macrophages by orthopaedic biomaterial particles. J Bone Miner Res 2003; 18: 1573-1583, doi: 10.1359/jbmr.2003. 18.9.1573.
21. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342, doi: 10.1038/nature01658.
22. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, et al. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am 1999; 81: 603-615, doi: 10.1302/0301-620X.81B1.8884.
23. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, et al. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 2000; 18: 472-480, doi: 10.1002/jor.1100180321.
24. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, et al. Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci U S A 1999; 96: 4844-4849, doi: 10.1073/pnas.96.9.4844.
25. Boyce BF, Xing L, Franzoso G, Siebenlist U. Required and nonessential functions of nuclear factor-kappa B in bone cells. Bone 1999; 25: 137-139, doi: 10.1016/S8756-3282 (99)00105-2.
26. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584, doi: 10.1038/nature02006.
27. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005; 118: 3573-3584, doi: 10.1242/jcs.02554.
28. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 2000; 113 (Part 13): 2445-2453.
29. Valles G, Gonzalez-Melendi P, Gonzalez-Carrasco JL, Saldana L, Sanchez-Sabate E, Munuera L, et al. Differential inflammatory macrophage response to rutile and titanium particles. Biomaterials 2006; 27: 5199-5211, doi: 10.1016/j.biomaterials.2006.05.045.
30. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003; 23: 1027-1029.
31. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901, doi: 10.1016/S1534-5807(02)00369-6.
32. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol 2008; 3: 457-484, doi: 10.1146/annurev. pathmechdis.3.121806.151431.
33. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-3545, doi: 10.1073/pnas. 96.7.3540.
34. Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, et al. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. J Cell Sci 2012; 125: 2910-2917, doi: 10.1242/jcs.099986.
35. Yamazaki M, Fukushima H, Shin M, Katagiri T, Doi T, Takahashi T, et al. Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J Biol Chem 2009; 284: 35987-35995, doi: 10.1074/jbc.M109.070540.
36. Hong JH, Lee GT, Lee JH, Kwon SJ, Park SH, Kim SJ, et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 2009; 128: e442-e450, doi: 10.1111/j.1365-2567.2008.02998.x.
37. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007; 77: 626-631, doi: 10.1111/j.1445-2197.2007.04175.x.
38. Jager M, Emami R, Thorey F, Krauspe R. Saving implants BMP-2 application in revision total hip surgery. Int J Biomed Sci 2006; 2: 187-195.
39. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001; 16: 1787-1794, doi: 10.1359/jbmr.2001.16. 10.1787.
40. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998; 9: 49-61, doi: 10.1016/S1359-6101(97)00036-1.